A survey by the consumer group has found the average GP gets seven visits from a pharmaceutical sales person every month, with a third getting more than 10.
A handful of the 180 doctors surveyed admitted seeing more than 20 sales people a month.
But only one third said they had ever seen the independent equivalent of the sales reps, the government-funded National Prescribing Services medical educators.
Choice said the findings were "concerning" and indicated the strong influence drug companies were exercising over the people who could recommend their medications.
"Choice is concerned about the level of access that pharmaceutical company drug representatives have to GPs relative to independent sources of information," said the organisation's health policy officer Michael Johnston.
The report showed that, in addition to visits, 62 per cent of GPs received 10 or more promotional mail-outs about drugs every week.
While most said they were happy to receive the information, and agreed it was better than nothing, 35 per cent said they often felt "pressured" into meeting these salespeople.
And most said they wanted more access to balanced, independent information.
"What 60 per cent of surveyed GPs are telling us is that there aren't enough sources of independent information available for them to be able to keep abreast of new drugs without receiving visits from multiple pharma company drugs reps," Johnston said.
The consumer group called on the federal government to invest more money in independent medical education and suggested the cost be offset by a one-off reduction in the prices paid to pharmaceutical companies through the Pharmaceutical Benefits Scheme (PBS).
He said this would improve the cost-effectiveness of the PBS, which will cost the federal government $7 billion this year.
But Medicines Australia, the body representing pharmaceutical companies, defended the level of GP contact, saying companies were obligated to provide objective product information to prescribers.
"Doctors value interactions with representatives of the pharmaceutical industry and the opportunity for questions and discussion they present," a spokeswoman said.
